Our interest is centered in understanding the role of PPARs (Peroxisome proliferator activated receptors) in the regulation of cell differentia­tion and lipid homeostasis in neurons. PPARs are the target of peroxisome proliferators, including hypolipidemic compounds used in the treatment of hyperlipemia, and of the thiazolendione anti­diabetic drugs. They are activated by natural fat­ty acids and their metabolites (eicosanoids) and belong to the subfamily of nuclear receptors that includes the retinoic acid receptors (RARs) and thyroid hormone receptor (TRs). The PPAR sub­family is composed of three distinct subtypes, PPARalpha, PPARbeta and PPARgamma that form heterodimers with the retinoid X recep­tor (RXR). PPARalpha modulates the pleiotropic effects of peroxisomal proliferators, regulat­ing genes involved in lipid catabolism, whereas PPARgamma affects key pathways in a variety of diseases, including insulin resistance and Syn­drome X. PPARbeta is important in controlling other PPARs and in wound healing. PPARs have been best studied in systemic lipid metabolism, being involved in obesity, diabetes and cancer. Much less is known about their role in the ner­vous system. We have evidence to consider these receptors as potential pharmacological targets in the treatment of neurodegenerative diseases.

Work Team

Contact The Team

Name

Subject

Email

Message

Type the text of the image: